Tcr2 Therapeutics Inc (NASDAQ:TCRR) Expected to Announce Earnings of -$0.65 Per Share

Wall Street analysts forecast that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.67). Tcr2 Therapeutics reported earnings per share of ($16.22) in the same quarter last year, which would suggest a positive year-over-year growth rate of 96%. The business is scheduled to report its next earnings report on Monday, April 6th.

On average, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($5.10) per share for the current fiscal year, with EPS estimates ranging from ($6.56) to ($4.32). For the next fiscal year, analysts expect that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.21) to ($1.91). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Tcr2 Therapeutics.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Tcr2 Therapeutics in a research report on Wednesday, December 11th. Zacks Investment Research cut shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $25.00.

Shares of Tcr2 Therapeutics stock traded up $0.24 on Friday, hitting $13.48. 64,600 shares of the company traded hands, compared to its average volume of 76,700. The stock has a market capitalization of $326.62 million and a P/E ratio of -0.61. Tcr2 Therapeutics has a 52 week low of $10.04 and a 52 week high of $25.47. The business has a 50-day simple moving average of $14.61 and a 200 day simple moving average of $15.62.

In related news, major shareholder Morana Jovan-Embiricos sold 7,743 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.65, for a total value of $136,663.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 150,623 shares of company stock worth $2,656,646 in the last 90 days. 39.07% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TCRR. BlackRock Inc. purchased a new position in Tcr2 Therapeutics during the second quarter worth $1,511,000. Vanguard Group Inc. purchased a new position in Tcr2 Therapeutics during the second quarter worth $1,070,000. Rhumbline Advisers purchased a new position in Tcr2 Therapeutics during the third quarter worth $162,000. First Trust Advisors LP purchased a new position in Tcr2 Therapeutics during the third quarter worth $474,000. Finally, State Street Corp boosted its stake in Tcr2 Therapeutics by 1,033.6% during the third quarter. State Street Corp now owns 166,634 shares of the company’s stock worth $2,505,000 after buying an additional 151,934 shares during the period. Institutional investors own 58.99% of the company’s stock.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

See Also: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.